-
Something wrong with this record ?
Rifampicin Does not Significantly Affect the Expression of Small Heterodimer Partner in Primary Human Hepatocytes
P. Pavek, L. Stejskalova, L. Krausova, M. Bitman, R. Vrzal, Z. Dvorak,
Language English Country Switzerland
Document type Journal Article
NLK
Directory of Open Access Journals
from 2010
Free Medical Journals
from 2010
PubMed Central
from 2010
Europe PubMed Central
from 2010
Open Access Digital Library
from 2010-01-01
Open Access Digital Library
from 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2010
- Publication type
- Journal Article MeSH
The small/short heterodimer partner (SHP, NR0B2) is a nuclear receptor corepressor lacking a DNA binding domain. SHP is induced by bile acid-activated farnesoid X receptor (FXR) resulting in CYP7A1 gene suppression. In contrast, Pregnane X receptor (PXR) activation by its ligands was recently suggested to inhibit SHP gene transactivation to maximize the induction of PXR target genes. However, there are also conflicting reports in literature whether PXR or rodent Pxr activation down-regulates SHP/Shp expression. Moreover, the PXR-mediated regulation of the SHP gene has been studied only at the SHP mRNA and transactivation (gene reporter assay) levels. In this study, we studied the effect of rifampicin, a prototype PXR ligand, on SHP mRNA, and protein expression in three primary human hepatocyte cultures. We found that SHP mRNA is not systematically down-regulated in hepatocyte in culture after 24 h treatment with rifampicin. Consistently, we did not observe down-regulation of SHP protein in primary human hepatocytes after 24 and 48 h of incubation with rifampicin. We can conclude that although we observed slight down-regulation of SHP mRNA and protein in several hepatocyte preparations, the phenomenon is unlikely critical for PXR-mediated induction of its target genes.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13016213
- 003
- CZ-PrNML
- 005
- 20250318105530.0
- 007
- ta
- 008
- 130424s2012 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fphar.2012.00001 $2 doi
- 035 __
- $a (PubMed)22291651
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Pavek, Petr $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague Hradec Kralove, Czech Republic.
- 245 10
- $a Rifampicin Does not Significantly Affect the Expression of Small Heterodimer Partner in Primary Human Hepatocytes / $c P. Pavek, L. Stejskalova, L. Krausova, M. Bitman, R. Vrzal, Z. Dvorak,
- 520 9_
- $a The small/short heterodimer partner (SHP, NR0B2) is a nuclear receptor corepressor lacking a DNA binding domain. SHP is induced by bile acid-activated farnesoid X receptor (FXR) resulting in CYP7A1 gene suppression. In contrast, Pregnane X receptor (PXR) activation by its ligands was recently suggested to inhibit SHP gene transactivation to maximize the induction of PXR target genes. However, there are also conflicting reports in literature whether PXR or rodent Pxr activation down-regulates SHP/Shp expression. Moreover, the PXR-mediated regulation of the SHP gene has been studied only at the SHP mRNA and transactivation (gene reporter assay) levels. In this study, we studied the effect of rifampicin, a prototype PXR ligand, on SHP mRNA, and protein expression in three primary human hepatocyte cultures. We found that SHP mRNA is not systematically down-regulated in hepatocyte in culture after 24 h treatment with rifampicin. Consistently, we did not observe down-regulation of SHP protein in primary human hepatocytes after 24 and 48 h of incubation with rifampicin. We can conclude that although we observed slight down-regulation of SHP mRNA and protein in several hepatocyte preparations, the phenomenon is unlikely critical for PXR-mediated induction of its target genes.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Stejskalova, Lucie
- 700 1_
- $a Krausova, Lucie
- 700 1_
- $a Bitman, Michal $7 xx0330075
- 700 1_
- $a Vrzal, Radim
- 700 1_
- $a Dvorak, Zdenek
- 773 0_
- $w MED00174597 $t Frontiers in pharmacology $x 1663-9812 $g Roč. 3 (2012), s. 1
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/22291651 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20130424 $b ABA008
- 991 __
- $a 20250318105527 $b ABA008
- 999 __
- $a ind $b bmc $g 979414 $s 814534
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 3 $d 1 $i 1663-9812 $m Frontiers in pharmacology $n Front Pharmacol $x MED00174597
- LZP __
- $a Pubmed-20130424